Study of Oral LOXO-338 in Patients With Advanced Blood Cancers

PHASE1Active, not recruitingINTERVENTIONAL
Enrollment

316

Participants

Timeline

Start Date

September 30, 2021

Primary Completion Date

June 14, 2023

Study Completion Date

December 31, 2025

Conditions
Leukemia, Lymphocytic, Chronic, B-CellLymphoma, B-cell Marginal ZoneLymphoma, Non-HodgkinMultiple MyelomaB-cell LymphomaWaldenstrom MacroglobulinemiaLymphoma, Mantle-Cell
Interventions
DRUG

LOXO-338

Oral

DRUG

Pirtobrutinib

Oral

Trial Locations (23)

10065

Memorial Sloan Kettering Cancer Center, New York

30322

Emory University, Atlanta

31100

L'Institut Universitaire du Cancer de Toulouse Oncopole, Toulouse

32224

Mayo Clinic in Florida, Jacksonville

33136

Sylvester Comprehensive Cancer Center, Miami

33604

Centre hospitalier universitaire de Haut Leveque, Pessac

34295

CHRU de Montpellier-Hopital St Eloi, Montpellier

40138

IRCCS - AOU di Bologna, Bologna

44093

Centre Hospitalier Universitaire de Nantes - L' Hopital l'hôtel-Dieu, Nantes

46237

Indiana Blood & Marrow Transplantation (IBMT), Indianapolis

53226

Medical College of Wisconsin, Milwaukee

66205

University of Kansas Medical Center, Westwood

69495

Centre Hospitalier Lyon Sud, Pierre-Bénite

75248

Institut Curie, Paris

85724

The University of Arizona Cancer Center, Tucson

94117

University of California San Francisco, Medical Center at Paranassus, San Francisco

98104

Swedish Medical Center, Seattle

91010-0269

City of Hope National Medical Center, Duarte

02111

Tufts Medical Center, Boston

55905-0002

Mayo Clinic, Rochester

60 185

Centrum Medyczne Pratia Poznan, Skorzewo

30-510

Pratia MCM Krakow, Krakow

02-781

Narodowy Instytut Onkologii im. Marii Sklodowskiej-Curie Panstwowy Instytut Badawczy, Warsaw

All Listed Sponsors
lead

Eli Lilly and Company

INDUSTRY